AC Immune SA (ACIU) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 immunotherapy for early Parkinson’s disease, showing a significant increase in anti-alpha-synuclein antibodies. The treatment was well tolerated, with no major safety concerns, and all patients responded positively. These findings could pave the way for further trials and potentially advance the treatment’s development.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue